The Compounding Pharmacy
Peptide Supplier
Purpose-built for licensed 503A and 503B compounding pharmacies. Research-grade peptide APIs with the documentation your compounding operations actually require — lot-traceable COAs, endotoxin testing, sterility confirmation, residual solvent panels, and NET 30 terms for qualifying pharmacy accounts.
503A vs 503B — How We Serve Both
503A patient-specific compounding pharmacies and 503B outsourcing facilities have different supply chain requirements. Our peptide API supply is structured to meet both — with documentation packages tailored to each framework.
503A Compounding Pharmacies
Prepare patient-specific prescriptions. Source APIs for individual compounding batches. Require lot-traceable documentation for each API used in each patient preparation.
- Lot-specific COA matching each shipment
- HPLC purity ≥98% + mass spec identity
- Endotoxin by LAL method (<1 EU/mg)
- Sterility documentation per lot
- Water content + residual solvents
- Smaller per-order quantities (MOQ 5–10 vials)
- NET 30 for qualifying pharmacy accounts
503B Outsourcing Facilities
Produce larger office-use batches without patient-specific prescriptions. Require pharmaceutical-grade APIs with expanded documentation for GMP-compliant batch production.
- All 503A documentation PLUS:
- Analytical method validation data
- Supplier qualification documentation
- Full GMP documentation package
- Higher-volume bulk orders supported
- Custom fill sizes available
- Dedicated account management
Contact our B2B desk to specify your pharmacy type and receive the appropriate documentation package with your first quote. 503B documentation packages require a qualification process — contact us at least 5 business days before your required delivery date.
What Every Compounding Pharmacy Peptide COA Must Include
A COA for compounding pharmacy use is not the same as a retail research peptide COA. The documentation standard for compounding pharmacy API supply covers each of the following fields — all of which we provide on every lot, available pre-purchase.
HPLC Purity ≥98%
Area percentage for the peptide peak. Method must resolve late-eluting fatty acid impurities for complex peptides (tirzepatide, semaglutide). Not just total purity — chromatogram available.
Mass Spectrometry Identity
Molecular weight confirmation per lot. Confirms the compound is what the label states — not just that 98% of something is present. Expected MW listed for each peptide on our catalog.
Endotoxin — LAL Method
Bacterial endotoxin testing by Limulus Amebocyte Lysate (LAL) method. Specification: <1 EU/mg per lot. Critical for injectable compounding applications.
Sterility Confirmation
Sterile-filtered, aseptic fill documentation. Sterility testing result confirmed per batch. Essential for all injectable peptide compounding operations.
Water Content — Karl Fischer
Water content by Karl Fischer titration. Specification: <5% per lot. Affects accurate dosing calculations in compounding — a high water content means less active peptide per nominal weight.
Residual Solvents
TFA, acetonitrile, DMF, and other synthesis solvents panel. ICH Q3C compliant. TFA content specifically should be tested and disclosed — a marker frequently omitted by non-pharmacy-grade suppliers.
Lot Number Traceability
Every COA carries a unique lot number that matches the vial labeling exactly. Lot numbers are maintained in our quality system for recall traceability — full chain of custody from production to delivery.
Analytical Method Validation
For 503B outsourcing facilities requiring expanded GMP documentation: analytical method validation data, stability data, and supplier qualification documentation available in our 503B documentation package.
Compounding Pharmacy Peptide Regulations — 2026 Status
The regulatory landscape for compounding pharmacy peptide supply has been actively evolving from 2023 through 2026. Understanding current FDA status for each compound is essential before placing bulk orders. The following is an informational summary — consult your regulatory counsel and monitor FDA.gov for authoritative current status.
FDA Category 2 Designation Wave
FDA began moving popular peptides to Category 2 of the 503A bulk substances list, restricting their use in patient-specific compounding. By late 2024, 19 peptides had been placed on the restricted list including BPC-157, TB-500, CJC-1295, ipamorelin, and thymosin alpha-1.
HHS Announcement — 14 Peptides Reinstated
February 2026 HHS announcement restored approximately 14 peptides to Category 1 compounding status, creating a regulated access channel through licensed compounding pharmacies with a valid prescription. Full formal Federal Register rulemaking ongoing.
FDA Category 2 Removals
FDA removed 12 additional peptides from Category 2 effective April 22, 2026. This action did not automatically add them to the 503A bulks list or authorize compounding — PCAC review is still required for formal reinstatement to Category 1.
PCAC Review — Multiple Peptides Under Evaluation
The Pharmacy Compounding Advisory Committee (PCAC) meetings scheduled July 23–24, 2026 will evaluate CJC-1295, ipamorelin, thymosin alpha-1, AOD-9604, and selank for potential inclusion on the 503A bulks list. Positive PCAC recommendations would create a formal 503A compounding pathway for these compounds.
Important: This regulatory summary is for informational context only and does not constitute legal or regulatory advice. Compounding pharmacy buyers must verify the current FDA compounding status of each specific peptide with their regulatory counsel before ordering. Status is subject to change — monitor FDA.gov and the Federal Register for authoritative updates.
Compounding Pharmacy Peptide Catalog — All SKUs with Status
The following peptide APIs are available for purchase. Compounding status column reflects our current understanding as of May 2026 — verify with your regulatory counsel before ordering for compounding use.
| Peptide API | Size | Price From | Compounding Status (May 2026) | Full Specs |
|---|---|---|---|---|
| Tirzepatide | 5mg–30mg | $93 | Verify FDA guidance | View → |
| Semaglutide | 5mg | $81 | Verify FDA guidance | View → |
| Retatrutide | 5mg–30mg | $93 | Research use | View → |
| BPC-157 | 5mg | $33 | Cat 2 — research use | View → |
| GHK-Cu | 50mg | $34 | Verify FDA guidance | View → |
| BPC-157 TB-500 Blend | 5mg+5mg | $68 | Research use | View → |
| CJC-1295 Ipamorelin | 5mg+5mg | $61 | PCAC July 2026 review | View → |
| NAD+ | 500mg | $102 | Generally available | View → |
| PT-141 (Bremelanotide) | 10mg | $28 | Verify FDA guidance | View → |
| Sermorelin | 2mg | $18 | 503A available | View → |
Status Note: "Generally available" and "503A available" indicate our current understanding — verify with regulatory counsel. "Verify FDA guidance" and "PCAC review" indicate compounds with evolving status requiring pharmacy-specific legal review. "Research use" indicates compounds currently classified as Category 2 or without 503A authorization — available for licensed research buyers only.
Ready to Set Up Your Pharmacy Account?
NET 30 · Lot-traceable COAs · 10 SKUs in stock · 48h fulfillment · 503A & 503B served
Compounding Pharmacy Peptide Supplier — FAQ
Full Peptide API Catalog
Research Use & Regulatory Disclaimer: All peptide APIs listed on this page are sold for research, laboratory, and licensed compounding use only. Regulatory status summaries are provided for informational context only and do not constitute legal or regulatory advice. Compounding pharmacy buyers are solely responsible for verifying the current FDA compounding authorization status of each specific compound before use in compounding operations. Consult your regulatory counsel and monitor FDA.gov and the Federal Register for authoritative and current compounding status information. Not for general consumer sale.
Wholesale Peptides for Compounding Pharmacies
- Tirzepatide Wholesale — High-demand metabolic peptide used in advanced compounding workflows.
- Semaglutide Wholesale — GLP-1 peptide commonly requested in pharmacy compounding programs.
- BPC-157 Wholesale — Research peptide often included in regenerative compounding formulations.
- NAD+ Wholesale — Longevity compound used in IV and regenerative pharmacy protocols.
- GHK-Cu Wholesale — Copper peptide used in dermatology and anti-aging compounding applications.